Editorial Commentary: Sexual networks, sex hormones, and recurrent bacterial vaginosis: Not such strange bedfellows

Clinical Infectious Diseases

Volumn 56, Issue 6, 2013, Pages 787-879

  Marrazzo, Jeanne M ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

bacterial vaginosis; hormonal contraception; lactobacilli; microbiome; sexually transmitted infections

Indexed keywords

CLINDAMYCIN; DESOGESTREL PLUS ESTRADIOL; ESTRIOL; ETHINYLESTRADIOL; METRONIDAZOLE; PLACEBO; PROBIOTIC AGENT; SEX HORMONE;

ANTIBIOTIC THERAPY; DISEASE TRANSMISSION; HORMONAL CONTRACEPTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LACTOBACILLUS ACIDOPHILUS; MICROBIOME; NOTE; ORAL CONTRACEPTION; PRIORITY JOURNAL; RECURRENT DISEASE; SEXUAL BEHAVIOR; SEXUALITY; SEXUALLY TRANSMITTED DISEASE; VAGINA EPITHELIUM; VAGINA RING; VAGINITIS;

ANTI-INFECTIVE AGENTS; CLINDAMYCIN; CONTRACEPTIVE AGENTS; FEMALE; HUMANS; METRONIDAZOLE; PROBIOTICS; SEXUAL BEHAVIOR; VAGINOSIS, BACTERIAL;

EID: 84874785208     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cis1034     Document Type: Note

References (11)

1. Sobel JD, Ferris D, Schwebke J, et al. Suppressive antibacterial therapy with 0.75% metronidazole vaginal gel to prevent recurrent bacterial vaginosis. Am J Obstet Gynecol 2006; 194:1283-9.
2. Goldenberg RL, Thom E, Moawad AH, Johnson F, Roberts J, Caritis SN. The preterm prediction study: fetal fibronectin, bacterial vaginosis, and peripartum infection. NICHD Maternal Fetal Medicine Units Network. Obstet Gynecol 1996; 87:656-60.
3. Sweet RL. Gynecologic conditions and bacterial vaginosis: implications for the nonpregnant patient. Infect Dis Obstet Gynecol 2000; 8:184-90.
4. Bradshaw CS, Pirotta M, De Guingand D, et al. Efficacy of oral metronidazole with vaginal clindamycin or vaginal probiotic for bacterial vaginosis: randomised placebocontrolled double-blind trial. PLoS One 2012; 7:e34540.
5. Fethers KA, Fairley CK, Morton A, et al. Early sexual experiences and risk factors for bacterial vaginosis. J Infect Dis 2009; 200: 1662-70.
6. Heffron R, Donnell D, Rees H, et al. Use of hormonal contraceptives and risk of HIV-1 transmission: a prospective cohort study. Lancet Infect Dis 2012; 12: 19-26.
7. Keller MJ, Guzman E, Hazrati E, et al. PRO 2000 elicits a decline in genital tract immune mediators without compromising intrinsic antimicrobial activity. AIDS (London, England) 2007; 21:467-76.
8. King AE, Critchley HO, Kelly RW. Innate immune defences in the human endometrium. Reprod Biol Endocrinol 2003; 1:116.
9. King AE, Fleming DC, Critchley HO, Kelly RW. Differential expression of the natural antimicrobials, beta-defensins 3 and 4, in human endometrium. J Reprod Immunol 2003; 59:1-16.
10. Veres S, Miller L, Burington B. A comparison between the vaginal ring and oral contraceptives. Obstet Gynecol 2004; 104:555-63.
11. Thurman AR, Clark MR, Doncel GF. Multipurpose prevention technologies: biomedical tools to prevent HIV-1, HSV-2, and unintended pregnancies. Infect Dis Obstet Gynecol 2011; 2011:1-10.